Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Ionis rare disease candidate ekes out phase 3 win
Out of 54 patients with Alexander disease, those given zilganersen could walk an average of 33.3% faster in a 10-meter walk test at 61 weeks.
Darren Incorvaia
Sep 22, 2025 10:46am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
Cytokinetics’ ph. 3 cardio win sends stock soaring
Sep 2, 2025 2:05pm
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Aug 13, 2025 1:48pm
Biohaven trashes troriluzole in OCD after ph. 3 fail
Aug 12, 2025 2:06pm
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
